Physician profile
John Paciuc
NPI 1487796405
$8,925.76
in general payments reported to CMS, 2019-2025
14 companies · $408 in 2025
The $408 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2022: $1,729 · 2023: $3,175 · 2024: $3,022 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Consulting Fee: $1,500 · Honoraria: $1,500 · Food and Beverage: $1,044 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Consulting Fee | $1,500.00 |
| Honoraria | $1,500.00 |
| Food and Beverage | $1,043.87 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $6,943.26 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $389.45 | 2022-2025 | |
| Abbvie INC. | $273.84 | 2022 | |
| Astellas Pharma US INC | $224.87 | 2023-2025 | Veozah |
| Renovia INC | $189.65 | 2019 | |
| Therapeuticsmd, INC. | $128.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.42 | 2023 | Andexxa |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Myfembree |
| Lilly USA, LLC | $125.00 | 2025 | Zepbound |
| Myovant Sciences INC. | $124.41 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $118.73 | 2019 | |
| Ibsa Pharma INC. | $18.88 | 2023 | Tirosint, Licart |
| Allergan, INC. | $16.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paciuc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.